Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David F Penson

Showing results (451-460 of 570) with videos related to

Pageof 57
Sort By:
The Journal of Urology|August 21, 2012
Racial variation in the quality of surgical care for prostate cancerDaniel A Barocas, Darryl T Gray, Jay H Fowke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2016
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE TrialDavid F Penson, Andrew J Armstrong, Raoul Concepcion, et al.
The Journal of Urology|March 15, 2013
Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processingMarc A Bjurlin, H Ballentine Carter, Paul Schellhammer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2016
Reply to M.A.N. Şendur et al and J. MichelsDavid F Penson, Andrew J Armstrong, Raoul Concepcion, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2003
General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes studyDavid F Penson, Ziding Feng, Alan Kuniyuki, et al.
The Journal of Urology|May 18, 2026
<b>Cost-Effectiveness of Immune Checkpoint Inhibitor Therapy plus BCG for High-Risk Non-muscle Invasive Bladder Cancer: Analyses of CREST</b>, <b>POTOMAC, and ALBAN</b>Daniel D Joyce, Vidit Sharma, Grace E Ratcliff, et al.
Urologic Oncology|January 22, 2017
TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinomaZachary A Glaser, Harold D Love, Shunhua Guo, et al.
The Journal of Urology|October 26, 2018
Perioperative Oral Nutrition Supplementation Reduces Prevalence of Sarcopenia following Radical Cystectomy: Results of a Prospective Randomized Controlled TrialChad R Ritch, Michael S Cookson, Peter E Clark, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2017
Treatment Decision Regret Among Long-Term Survivors of Localized Prostate Cancer: Results From the Prostate Cancer Outcomes StudyRichard M Hoffman, Mary Lo, Jack A Clark, et al.
Psycho-Oncology|June 15, 2017
Decision-making processes among men with low-risk prostate cancer: A survey studyRichard M Hoffman, Stephen K Van Den Eeden, Kimberly M Davis, et al.
Pageof 57

Showing results (451-460 of 570) with videos related to

Sort By:
Pageof 57
The Journal of Urology|August 21, 2012
Racial variation in the quality of surgical care for prostate cancerDaniel A Barocas, Darryl T Gray, Jay H Fowke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2016
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE TrialDavid F Penson, Andrew J Armstrong, Raoul Concepcion, et al.
The Journal of Urology|March 15, 2013
Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processingMarc A Bjurlin, H Ballentine Carter, Paul Schellhammer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2016
Reply to M.A.N. Şendur et al and J. MichelsDavid F Penson, Andrew J Armstrong, Raoul Concepcion, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2003
General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes studyDavid F Penson, Ziding Feng, Alan Kuniyuki, et al.
The Journal of Urology|May 18, 2026
<b>Cost-Effectiveness of Immune Checkpoint Inhibitor Therapy plus BCG for High-Risk Non-muscle Invasive Bladder Cancer: Analyses of CREST</b>, <b>POTOMAC, and ALBAN</b>Daniel D Joyce, Vidit Sharma, Grace E Ratcliff, et al.
Urologic Oncology|January 22, 2017
TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinomaZachary A Glaser, Harold D Love, Shunhua Guo, et al.
The Journal of Urology|October 26, 2018
Perioperative Oral Nutrition Supplementation Reduces Prevalence of Sarcopenia following Radical Cystectomy: Results of a Prospective Randomized Controlled TrialChad R Ritch, Michael S Cookson, Peter E Clark, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2017
Treatment Decision Regret Among Long-Term Survivors of Localized Prostate Cancer: Results From the Prostate Cancer Outcomes StudyRichard M Hoffman, Mary Lo, Jack A Clark, et al.
Psycho-Oncology|June 15, 2017
Decision-making processes among men with low-risk prostate cancer: A survey studyRichard M Hoffman, Stephen K Van Den Eeden, Kimberly M Davis, et al.
Pageof 57